Archive · 6 Jan 2026
Cathie Wood Bets Big on Genomics Stocks in 2026
Cathie Wood, a well-known investor, is making big bets on companies that work on gene editing.
These companies use advanced technology to fix genetic problems that can cause diseases.
Wood believes that artificial intelligence will help make this technology even better and faster.
She is investing a lot of money in these companies, like Beam Therapeutics and CRISPR Therapeutics, while selling some of her older tech investments.
However, there are risks because these companies are still in early stages and need to pass many tests before they can succeed.
Wood thinks that gene editing will become very important in the future, and she wants to be ready for it.
Cathie Wood's ARK Invest is heavily investing in gene-editing companies like Beam Therapeutics and CRISPR Therapeutics.
ARK Invest has allocated over 5% of its flagship fund to CRISPR Therapeutics and 3.41% to Beam Therapeutics.
Wood is selling shares in companies like Tesla, Roku, and Shopify to fund these new investments.
She believes AI will accelerate the genomics revolution by making gene sequencing faster and cheaper.
The success of these investments depends on clinical trials, regulatory approvals, and insurance reimbursement.
- Who
- Cathie Wood and ARK Invest
- What
- Investing heavily in genomics and gene-editing companies
- When
- 2026
- Where
- Global market, primarily in the biotech sector
- Why
- Belief in the potential of gene editing to cure diseases and the role of AI in advancing the technology
- Investor
- Cathie Wood
- Fund
- ARK Invest
- Key Companies
- Beam Therapeutics, Intellia Therapeutics, CRISPR Therapeutics, Pacific Biosciences
- Investment Amount
- $5.4 billion
- Portfolio Allocation
- CRISPR Therapeutics: 5%, Beam Therapeutics: 3.41%
- Technology Focus
- Gene Editing, Base Editing, AI Integration
- Risks
- Pre-revenue, Clinical Trials, Regulatory Approvals, Insurance Reimbursement